Exploration of the Relationship between Interleukins 17, 37 and 38 with Vitamin E in Iraqi Men with CHB.

IOP Conf. Series: Journal of Physics: Conf. Series **1294** (2019) 052047 doi:10.1088/1742-6596/1294/5/052047

Exploration of the Relationship between Interleukins 17, 37 and 38 with Vitamin E in Iraqi Men with CHB.

Shakir F Tuleab Alaaraji

Department of Chemistry –College of Education for Pure Sciences-University of Anbar, Ramadi, Anbar, Iraq.

Email : dr.shakir.chemist@gmail.com

Abstract. Hepatitis B is a possibly life-threatening liver contagion produced by the hepatitis B virus (HBV). It is a main worldwide health issue. It can cause chronic contagion & puts societies at great danger of death from cirrhosis & liver malignancy. The goal of the current research was to measure four important parameters in cases with chronic hepatitis B (CHB) (the amount of IL-17, IL-37, IL-38 & vitamin E). These factors were surveyed in CHB patients to compare with healthy controls & study the association among these markers with other parameters in the study. Population consists of 40 patients diagnosed with CHB & a healthy controls (HC) group of 39 person. IL-17, IL-37, IL-38 & vitamin E levels were assessed in all subjects by using available ELISA kits from Mybiosource company; USA. serum concentrations of IL-17 & IL-37 were importantly greater in HBV group compared to control group, while serum levels of IL-38 & vitamin E were importantly lesser in CHB cases compared to HC also vitamin E showed weakly negative correlation with IL-17 & weakly positive correlation with IL-37 & IL-38. The study recommends that IL-17 & IL-37 levels may be a useful indicator to identification HBV in primary phases so that we should monitor these markers concentrations in blood of constantly to sustain their health.

Key words: CHB , interleukin-17 , interleukin-37 , interleukin-38

Introduction

Hepatitis B is a chief reason of liver infections producing CHB virus contagion in an expected 400 million persons worldwide [1]. Although progresses in the growth of particular antiviral treatment, together acute & chronic HBV contagions remain to be significant international health complications. Hepatitis B stays the first reason of liver cirrhosis internationally [2].

There are dual main treatment approaches which are useful for HBV cure: direct substitute anti-viral medications & immune-modulatory mediators [3]. Nevertheless, no one of existing treatments cans totally treatment CHBV contagion & extra active treatments are required for HBV management. Interleukins (ILs) affect the determination of HBVcontinuing contagion & the size of liver injury. Causes for remains HBV contagion are unspecified; however they are perhaps linked to host immune elements. Interleukins are recognized to exert a important functions in host immune answers. In CHB cases, the level of concentration Th17-cells (manufacturing IL-17) elevated through infection development from CHB 4.34% to acute-on chronic liver failure 5.62% cases compared to HC 2.42% [4]. Amongst immune de-regulations, persons linked to sub-type 17 of the T-helper lymphocyte (Th17)/interleukin-17 (IL-17) axis have been documented as main immune-pathological & predictive

components in cases with CHB. The pro inflammatory interleukin IL-17A perhaps stimulate neutrophils, connect to tissue irritation, fibrosis, & stimulate development of auto-immune infections [5, 6].

IL-37 is a modern interleukin of the IL-1 family that is expressed in a diversity of tissues & cells like monocytes, Natural killer (NK) cells, & activated B cells [7]. IL-37 protein can exist up-regulated via some pro-inflammatory interleukins & inflammatory activators [8]. Furthermore expression of IL-37 in macrophages or epithelial cells virtually totally reserved the production of pro inflammatory interleukins & innate immunocytes [9]. Although the anti inflammatory mechanism stays indistinct, IL-37 is secreted into extra cellular area to prevent the receptor of pro inflammatory interleukins or finds to the nucleus & relates intracellularly with Smad3 [9]. Furthermore, it has been stated that IL-37 has an important protective function in Concanavalin A-Induced Hepatitis [10], & Ischemia/ Reperfusion-Induced Hepatitis model in-vivo [11].

Interleukin (IL)-38 remained initially cloned as member of IL-1 family (IL-1F) cytokine [12]. Eighteen years later its detection, function of IL-38 is not unwell assumed. IL-38 goes to the IL-1F, & greatest of the sub-families are documented as proinflammatory interleukin that may control the expression of genes associated to inflammatory infections. Nevertheless, new results revealed IL-38 utilizes antiinflammatory roles, particularly on macrophages, via inhibiting production of proinflammatory interleukins, connect to decrease Th17 development, thus, creation this interleukin of importance for directing many prolonged inflammatory infections [13].

Vitamin E (Vit.E) is a lipid solvable anti-oxidant which keep the polyunsaturated fatty acids in membranes against the oxidation, control the making of reactive oxygen species (ROS), reactive nitrogen species (RNS) & control indication transduction. Immune modulatory properties of Vit.E have been detected in animal models below usual & infection situations. By progresses in devaluing of the growth, role, & directive of dendritic cells (DCs), macrophages, NK cells, T cells, & B cells, modern researches have concentrated on Vit.E's properties on specific immune cells [14]. Vit.E has been revealed to raise the cell division & IL-2 creating capacity of naïve T cells, raise the proportion of T cells accomplished of making an active immune synapse, & opposite the age-linked imperfection in the phosphorylation of LAT (linker for activation of T cells) in T cells from old animals [15]. Vit.E appears to control Th-1 & Th-2 reactions. The division of CD4 T cells to Th-1 or Th2 cells may associations with the defense adversary diverse pathogens (intra-cellular vs. extra-cellular pathogens) & the increase of diverse kinds of prolonged infections [16].

Material & Methods

The study was conducted on 40 CHB patients, the age range within 19→41years randomly carefully chosen from persons joining the Al-Fallujah teaching hospital & many private laboratories. No patient was getting any long-lasting pharmacological treatment known to effect fat equilibrium for 6 months earlier the start of the study or antioxidant vitamins throughout the study passage. HC group includes of 39 person, the age fluctuate between 20→40 years with no medical signs of every illness. Wholly blood samples were taken from the ulnar vein, in the before lunch. All cases & HC experienced full history taking& medical investigation involving determining ALT, AST, GGT & T. BIL.

The analysis of the following markers in the serum was performed: IL-17, IL-37, IL-38 & Vit. E. Serum IL-17, IL-37, IL-38 & Vit. E were estimated by enzyme linked immunosorbent assay (ELISA) Kits manufactured by (My-bio-source company, USA).

Statistical Analysis

Expressive investigation was done. Definite data are offered as a tables, & measurable documents were evaluated via the Statistical Package for Social Sciences (SPSS version 24) & GraphPad prism version 7. The statistical importance, trend & power of linear relationship among two measureable parameters, was calculated via Pearson rank linear correlation coefficient, All values are expressed as mean ± S.D., $P<0.05$ was reflected statistically important for all variables.

Results

Table 1 shows the st&ard demographic characteristics of HC & CHB cases. Together controls & cases were compatible with respect to age (29.80±6.90 vs 31.00 ± 8.90 years).

There was a significant increase in serum IL-17 & IL-37 in CHB patients (67.12 ± 20.14 pg/mL) & (164.77 ± 64.43 pg/mL) compared with normal subjects (12.84 ± 7.23 pg/ml) & (52.53 ± 21.43 pg/ml) respectively (figures 1-A & 1-B) (P < 0.001).CHB patients also had a significantly higher ALT, AST, GGT, & T.BIL compared with normal subjects (65.37 ± 18.64 vs 17.38 ± 5.52 IU/ml, P<0.001), (49.22 ± 16.20 vs 17.10 ± 7.30 IU/mL, P<0.001), (83.30 ± 30.24 30.89 ± 11.74 IU/mL, P<0.001) & (2.08 ± .63 vs .60 ±. 20 mg/dL, P < 0.001) respectively (table1), (figures 1-C, 1-D, 1-E & 1-G). IL-38 & Vit. E were significantly lower in CHB patients compared with normal subjects (58.55 ± 15.90 vs 206.64 ± 64.77 pg/mL, P<0.001) & (13.97 ± 5.78 vs 50.07 ± 19.22 µg/mL, P < 0.001) respectively (table1), (figures 1-I & 1-F).

Table 1: Comparison of demographics & biochemical profiles of controls & CHB cases

Parameters			Mean ± S. D	S. error	p-value
Age	**Years**	cases	31.00 ± 8.90	0.68	0.260
		controls	29.80 ± 6.90	0.57	
IL-17	**pg/mL**	cases	67.12 ± 20.14	3.19	<0.001
		controls	12.84 ± 7.23	1.19	
IL-37	**pg/mL**	cases	164.77 ± 64.43	10.19	<0.001
		controls	52.53 ± 21.43	3.43	
IL-38	**pg/mL**	cases	58.55 ± 15.90	2.52	<0.001
		controls	206.64 ± 64.77	10.37	
Vit. E	**µg/mL**	cases	13.97 ± 5.78	0.91	<0.001
		controls	50.07 ± 19.22	3.08	
ALT	**U/L**	cases	65.37 ± 18.64	2.95	<0.001
		controls	17.38 ± 5.52	0.88	
AST	**U/L**	cases	49.22 ± 16.20	2.65	<0.001
		controls	17.10 ± 7.30	1.69	
GGT	**U/L**	cases	83.30 ± 30.24	4.78	<0.001
		controls	30.89 ± 11.74	1.88	
T. BIL	**mg/dL**	cases	2.08 ± 0.63	0.10	<0.001







Figure (1): Comparison between different biochemical parameters in studied groups

As shown in table no. (2). Vit. E correlated very weakly positive & non-significant with IL-17 in CHB patients (r=0.156), Pearson relationship investigates revealed that Vit. E linked weakly positive with IL-37 & IL-38 (r=-0.084; r=-0.067 respectively). While Pearson connection investigates indicated that Vit. E weakly positive relationship with ALT, AST & GGT (r=0.287; r=0.182 & r=0.176) respectively, & showed weakly negative correlation with T.BIL. (r=- 0.091), while IL-37 correlated weakly negative with ALT & GGT (r=-0.475, p<0.01; r=-0.338, p<0.05) respectively, & slight positive with T.BIL. (r=0.390, p<0.05). IL-37 showed weakly positive relationship with IL-38 (r= 0.341, p<0.05), but it showed weakly positive relationship with T.BIL. (r= 0.390, p<0.05).

Table (2): Pearson association coefficients of Vit E with parameters which studied

		IL-17 pg/ml	IL-38 pg/ml	IL-37 pg/ml	Vit. E µg/ml	ALT U/L	AST U/L	GGT U/L	T. BIL mg/dl
IL-17	Pearson Correlation	1	-.098	.095	.156	.112	-.090	.169	.079
pg/ml	Sig. (2-tailed)		.549	.560	.336	.492	.579	.298	.628
IL-38	Pearson Correlation		1	.341*	-.067	-.210	.172	-.230	.377*
pg/ml	Sig. (2-tailed)			.031	.680	.194	.288	.154	.017
IL-37	Pearson Correlation			1	-.084	-.475**	.172	-.338*	.390*
pg/ml	Sig. (2-tailed)				.607	.002	.289	.033	.013
Vit. E	Pearson Correlation				1	.287	.182	.176	-.091
µg/ml	Sig. (2-tailed)					.073	.262	.278	.575

*. Represent p < 0.05

**. Represent p < 0.01

Discussion

The key lifecycle of HBV containing contagion, duplication, association, growth, & excretion. Established on the broad exploration of virus-host communications, numerous different mediators who intended to improve the innate & adaptive immune reactions [17] are below expansion to treatment HBV. Cytokines ensure a unique function in the immune-system & extensively include in diversities of biological developments, like antibody excretion, interferon-γ manufacture, cell proliferation & differentiation [18]. It is familiar that cytokine may disturb the biological developments of various viruses. IL-22 does not have important result on lethal influenza contagion, nevertheless is useful to sub-lethal contagion [19]. IL-32 has a defensive function in the immune reaction to RNA & DNA viruses [20]. Extra vitally, IL-26 was recognized to powerfully increase vesicular stomatitis virus contagion & duplication degrees IL-23 could similarly prevent human cytomegalovirus & has no influence the herpes simplex virus type 1 [21]. Previous researches powerfully showed that cytokines, even the similar one interleukin, shows diverse function in diverse virus contagion & sometime utilize absolutely diverse influence [22]. Until now, there is no explosion around the association among Vit. E with IL-17, IL-37 & IL-38 in CHB patients. In this study, we documented that IL-37 & IL-17 were expressively elevated in the serum of CHB cases compared to HC, however Vit. E & IL-38 were importantly lowered in the serum of CHB cases compared to HC.

Interleukin 17 (IL‑17) was chiefly recognized as a transcription from a rodent T‑cell hybridoma via 1993 [23]. It was distinct as a proinflammatory interleukin manufactured via innate & adaptive immune cells [24]. IL-17 creating cells are involved in numerous liver infections [25] & noticed in the tumor microenvironment [26]. As IL17 receptor (IL-17R) is expressed on wholly forms of liver cells [27].

Liver fibrosis is a significant pathological development in the increase of liver hepatitis, which submits that IL-17 might show a central function in the fibrogenesis & development of CHB. Certain studies have established that the cytokines like TGF-β, IL-6, IL-1, & TNF-α exert vital portions in the pathogenesis of liver fibrosis & cirrhosis in CHB [28]. It is narrowly associated with certain interleukins. TGF-β, collected using DC-derived IL-6, is necessary for de novo differentiation of IL-17-manufacturing T cells from naive CD4 T cells in vitro, a method that is augmented via IL-1β & TNFα [29].

Generally, IL37 is expressed in irritated tissue & not in tissues from HC. As a result, IL-37 repeals pro-inflammatory interleukin in stimulated & latent macrophage cell line. It is a normal preventer of immune reactions & may performance as a interleukin by together intracellular & extracellular actions [30].

IL-37 importantly decreases natural & LPS encouraged expression of IL-lα, lβ, 8, & TNF in human monocytic cell line & similarly destroys IL-l β-prompted expression of IL-I α, 8, 6, 23, lRA, 17, 18, IFN-γ & TNF in some diverse cell kinds. IL37 prevents cJun encouraged via IL-1 & similarly decreases phosphorylation ofp38 MAPK, a pro-inflammatory sign. Furthermore, it prevents M-CSF & GMCSF formed via stimulated DCs [31].

In this study, the concentrations of serum IL-37 in CHB cases with irregular concentrations of serum ALT (>50U/L) or AST (>40U/L) were greater than those with regular concentrations of ALT (<50U/L) or AST (<40U/L). Consequently, we assumed that the augmented IL-37 concentrations were go with higher concentrations of serum ALT, to prevent the extreme inflammatory injury.

The function of IL-37 in chronic HBV contagion is not clear. In this work, we studied the concentrations of serum IL37 in HBV contagions & in HC. A virus load-dependent rise in the concentrations of IL-37 in HBV contagion was detected. Nold & others have stated that unhealthy synovial coating in rheumatoid arthritis limited greater quantities of IL-37 compared with HC; assistant the idea that interleukin encouragement induces the manufacture of IL-37, & then, endogenous IL-37 prevents over-expression inflammation introduced via innate pathways [32].

In the present study, we detect IL-38 as a different reactive biomarker for CHB, & determine its antiinflammatory functions. The importance in the direction of IL-38 in CHB situation get up from our & previous explanations that its expression is decreased in the serum of CHB cases, as compared with HC. IL-38 & IL-36Ra antagonists have anti-inflammatory functions via provoking the IL-36 pathways by a straight compulsory to IL-36 receptor with parallel affinities [33, 34].

Our results showed reveal a related function of IL38 in CHB cases assistant the proposition that the dysregulation of its expression could be pathogenic in HBV. Previous study has stated relations of complete IL- 38 levels & infection, augmented IL- 38 in the serum was originate to relate with continuing liver damage in CHB cases that were not on antiviral treatment, & the greater the concentration of IL- 38 the extra possible these cases reacted to treatment [35]. If IL- 38 is defensive or harmful in this situation stays to be explained, however documents from an investigational murine model of liver injury recommend that IL- 38 has protective properties through liver infection [36].

Macrophage, significant effector cells in the innate-immune reaction, function as antigen presenting cell, control NK cells & T cells via manufacturing cytokines, ROS, RNS & prostaglandins (PG). Cytokines create via T cells & additional immune cells can change the macrophages into different people with separate physiologies [37].

Vit.E has been revealed to raise the cell split & IL-2 manufacturing ability of naïve T cells, raise the proportion of T cells accomplished of making an actual immune synapse, & opposite the age-related deficiency in the phosphorylation of linker for activation of T cells in T cells from old animals [38]. Previous study via Mahmood *et al.*, where Vit.E giving (500 mg/day) for 3 months in 17 chronic hepatitis C (CHC) cases leading to decrease of serum ALT concentrations to 63 U/L from standard concentrations of 73 U/L[39]. Parallel outcomes were stated in another paper with a probable randomized double-sightless irritated over design in 23 CHC cases who were refractory to

interferon. Vit.E supplementation (800 U/day) for 12 weeks lowered serum ALT from 90 to 68 U/L at the finish of cure [40]. Nevertheless, together the above papers estimated the influence of Vit.E in CHC cases & not in those having CHB cases.

Vit. E, actuality an antioxidant has initiated a statistically important development in certain of the liver occupation markers & predictive signs as shown in previous paper which can stay described via its established hepatoprotective mechanisms which contain membrane equilibrium, decreased NF-κB stimulation, decreased TNF manufacture, & suppression of hepatic stellate cell stimulation [41].

From current study can confirmed that the greater the grade of liver fibrosis, the greater the concentrations of IL-17 & IL-37. This submits that IL-17 & IL-37 possibly could stimulate and regulate the amount of fibrosis. They can be used as significant markers of inflammatory action & fibrosis assessment & ultimately malignant transformation in chronic liver injury.

They may similarly stay a appreciated sign for infection development & diagnosis. Augmented expression of IL-17 & IL-37 in CHB diseased cases similarly supports a function for IL-17 & IL-37 in the contagion, however the precise mechanism of role requirements additional exploration. This study shows that in CHB cases, IL-38 & Vit. E supplementation may be improvement in liver function marker & predictive signs.

Additional investigations should be concentrated on the improvement of a vigorous plan via mixing the viral elements, inflammatory elements & medical elements of balancing predictive assessment to confirm great cogency of the valuation for CHB incidence estimate. While bigger studies containing additional quantity of patients must be done.

References

[1]. Harrington LE, Hatton RD, Mangan PR, *et al.,* Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 & 2 lineages. *Nat Immunol,* **(2005),** 6(11):1123–32.

[2]. Mc Clune AC, Tong MJ. Chronic hepatitis B & hepatocellular carcinoma. *Clin. Liver Dis.* **(2010),** 14(3):461–76.

[3]. Pham EA, Perumpail RB, Fram BJ, *et al.*, Future Therapy for Hepatitis B Virus: Role of Immunomodulators. *Current hepatology reports*. **(2016),** 15(4):237–44.

[4]. J.-Y. Zhang, Z. Zhang, F. Lin *et al.*, "Interleukin-17-producing CD4+ Tcellsincreasewithseverityofliverdamageinpatients with chronic hepatitis B,". *Hepatology*, **(2010),** 51(1): 81–91.

[5]. Klemann C, Schröder A, Dreier A, *et al.* Interleukin 17, produced by γδ T cells, contributes to hepatic inflammation in a mouse model of biliary atresia & is increased in livers of patients. *Gastroenterology*, **(2016),** 150:229-41.

[6]. Ray S, De Salvo C, Pizarro TT. Central role of IL-17/Th17 immune responses & the gut microbiota in the pathogenesis of intestinal fibrosis. *Curr Opin Gastroenterol* **(2014),** 30:531-538.

[7]. Bufler P, Azam T, Gamboni-Robertson F, et al,. A complex of the IL-1 homologue IL-1F7b & IL-18-binding protein reduces IL-18 activity. *Proc Natl Acad Sci U S A* **(2002),** 99(21):13723–28.

[8]. Nold MF, Nold-Petry CA, Zepp JA, *et al,*. IL-37 is a fundamental inhibitor of innate immunity. *Nat Immunol,* **(2010),** 11(11):1014–22.

[9]. Boraschi D, Lucchesi D, Hainzl S, et al,. IL-37: a new anti-inflammatory cytokine of the IL-1 family. *Eur Cytokine Netw*, **(2011),** 22(3):127–47.

[10]. Sakai N, Van Sweringen HL, Belizaire RM, *et al,*. IL-37 reduces liver inflammatory injury via effects on hepatocytes & non-parenchymal cells. *J Gastroenterol Hepatol,* **(2012),** 27(10):1609–16.

[11]. Bulau AM, Fink M, Maucksch C, *et al,*. In vivo expression of interleukin-37 reduces local & systemic inflammation in concanavalin a-induced hepatitis. *Sci World J,* **(2011),** 11:2480–90.

[12]. Lin H, Ho AS, Haley-Vicente D, *et al,*. Cloning & characterization of IL-1HY2, a novel interleukin-1 family member. *J Biol Chem*, **(2001),** 276:20597–602.

[13]. Xu WD & Huang AF. Role of Interleukin-38 in Chronic Inflammatory Diseases: A Comprehensive Review. Front. *Immunol.,* **(2018),** 9(1642):1-6.

[14]. Lee GY & Han SN. The Role of Vitamin E in Immunity. *Nutrients*, **(2018),** 10(1614):1-18
[15]. Marko, M.G.; Pang, H.J.; Ren, Z.; *et al,*. Vitamin E reverses impaired linker for activation of T cells activation in T cells from aged C57BL/6 mice. *J. Nutr.* **(2009),** 139, 1192–97.
[16]. Li-Weber, M.; Giaisi, M.; Treiber, M.K.; *et al,*. Vitamin E inhibits IL-4 gene expression in peripheral blood T cells. *Eur. J. Immunol.* **(2002),** 32: 2401–8.
[17]. Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver international: *official journal of the International Association for the Study of the Liver*. **(2016),** 36 Suppl 1:85–92.
[18]. Akdis M, Aab A, Altunbulakli C, *et al,*. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, & TNF-alpha: Receptors, functions, & roles in diseases. *The Journal of allergy & clinical immunology*. **(2016),** 138(4):984–1010.
[19]. Ivanov S, Renneson J, Fontaine J, *et al,*. Interleukin-22 reduces lung inflammation during influenza A virus infection & protects against secondary bacterial infection. *Journal of virology*. **(2013),** 87(12):6911–24.
[20]. Zepp JA, Nold-Petry CA, Dinarello CA, *et al,*. Protection from RNA & DNA viruses by IL-32. *Journal of immunology.* **(2011),** 186(7):4110–8.
[21]. Braum O, Klages M, Fickenscher H. The cationic cytokine IL-26 differentially modulates virus infection in culture. *PloS one*. **(2013),** 8(7):e70281.
[22]. Roh EY, Song EY, Yoon JH, *et al,*. Effects of interleukin-4 & interleukin-12B gene polymorphisms on hepatitis B virus vaccination. *Annals of hepatology*. (**2017),** 16(1):63–70
[23]. Bao S, Zheng J, Li N, *et al,*. Role of interleukin-23 in monocyte-derived dendritic cells of HBV-related acute-on-chronic liver failure & its correlation with the severity of liver damage. **Clinics & research in hepatology & gastroenterology**. **(2016),** 41(2):147–55
[24]. Liu YB, Shen J: Peritumoral neuropilin-1 & vegf receptor-2 expression increases time to recurrence in hepatocellular carcinoma patients undergoing curative hepatectomy. *Oncotarget*, **(2014),** 5:11121-32.
[25]. Cua DJ, Tato CM: Innate il-17-producing cells: The sentinels of the immune system. *Nat Rev Immunol*, **(2010),** 10:479-489.
[26]. Bertolino P: Interleukin-22, interleukin-17, & other cytokines: A wall is coming down. *Hepatology*, **(2008),** 47:345-48.
[27]. Su X, Ye J, Hsueh EC, *et al,*. Tumor microenvironments direct the recruitment & expansion of human th17 cells. *J Immunol*, (2010), 184: 1630-41.
[28]. Lafdil F, Miller AM, Ki SH, *et al,*. Th17 cells & their associated cytokines in liver diseases. *Cell Mol Immunol*, **(2010),** 7: 250-54.
[29]. Roeb E, Graeve L, Hoffmann R, *et al,*. Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines & dexamethasone in rat hepatocyte primary cultures. *Hepatology*, **(1993),** 18(6): 1437–42.
[30]. Veldhoen M, Hocking RJ, Atkins CJ, *et al,*. TGF beta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. *Immunity*, **(2006),** 24(2): 179–89.
[31]. Tete S., Tripodp D., Rosatp M. *et al,*. IL-37 (IL-lF7) the newest anti-inflammatory cytokine which suppresses immune responses & inflammation. *Int. J. Irnrnunopathol. PharrnacoI*. **(2012),** 25(1): 31-38
[32]. Aslani S, Hossein-Nezhad A, Mirzaei K, *et al,*. T&em repeats of the CATT element of macrophage migration inhibitoryfactor gene may predict gestational diabetes mellitus severity.*Eur J Inflamm*, **(2011),** 9:193-7.
[33]. van de Veerdonk, F. L., de Graaf, D. M., Joosten, L. A., *et al,*. Biology of IL-38 & its role in disease. *Immunol. Rev*. **(2018),** 281: 191–96
[34]. Bassoy, E. Y., Towne, J. E. & Gabay, C. Regulation & function of interleukin-36 cytokines. *Immunol. Rev.* **(2018),** 281: 169 –178

[35]. Wang HJ, Jiang YF, Wang XR, *et al,*. Elevated serum interleukin- 38 level at baseline predicts virological response in telbivudine- treated patients with chronic hepatitis B. *World J Gastroenterol.* **(2016),** 22: 4529-37.

[36]. Yuan X, Li Y,Pan X, *et al,*. IL- 38 alleviates concanavalin A- induced liver injury in mice. *Int Immunopharmacol*. **(2016),** 40: 452-57.

[37]. Mosser, D.M.; Edwards, J.P. Exploring the full spectrum of macrophage activation. *Nat. Rev. Immunol*. **(2008),** 8: 958–69.

[38]. Marko, M.G.; Pang, H.J.; Ren, Z.; *et al,*. Bunnell, S.C.; Meydani, S.N. Vitamin E reverses impaired linker for activation of T cells activation in T cells from aged C57BL/6 mice. *J. Nutr*. **(2009),** 139: 1192–97.

[39]. Mahmood S, Yamada G, Niiyama G, Kawanaka M, Togawa K, Sho M, et al. Effect of Vitamin E on serum aminotransferase & thioredoxin levels in patients with viral hepatitis C. *Free Radic Res,* **(2003),** 37:781‐5.

[40]. von Herbay A, Stahl W, Niederau C, *et al,*. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: A r&omized, double‐blind, placebo‐controlled study. *Free Radic Res,* **(1997),** 27:599‐605.

[41]. Ren, Z.; Pae, M.; Dao, M.C.; et al,. Dietary supplementation with tocotrienols enhances immune function in C57BL/6 mice. *J. Nutr.* **(2010),** 140:1335–41.